Combining Anti-Mir-155 With Chemotherapy for the Treatment of Lung Cancers

Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-16-1025
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

Nanoparticles for the Treatment of Lung Cancers

Journal of Young Pharmacists
ToxicologyPharmaceuticsPharmacology
2018English

Patients’ Retrospective Assessment of Palliative Chemotherapy for Lung or Gastrointestinal Cancers

Journal of Community and Supportive Oncology
OncologyHematology
2016English

Potential Diagnostic Value of miR-155 in Serum From Lung Adenocarcinoma Patients

Oncology Reports
MedicineCancer ResearchOncology
2013English

The Diagnosis and Treatment for Multiple Primary Lung Cancers.

Japanese Journal of Lung Cancer
OncologyRespiratory MedicinePulmonary
1991English

High Expression of miR-155 and miR-21 in the Recurrence or Metastasis of Non-Small Cell Lung Cancer

Oncology Letters
Cancer ResearchOncology
2019English

Predictive Relevance of miR‑34a, miR‑224 and miR‑342 in Patients With Advanced Squamous Cell Carcinoma of the Lung Undergoing Palliative Chemotherapy

Oncology Letters
Cancer ResearchOncology
2017English

Serum Levels of miR-29, miR-122, miR-155 and miR-192 Are Elevated in Patients With Cholangiocarcinoma

PLoS ONE
Multidisciplinary
2019English

Lactosylated Gramicidin-Based Lipid Nanoparticles (Lac-Gln) for Targeted Delivery of Anti-miR-155 to Hepatocellular Carcinoma

Journal of Controlled Release
Pharmaceutical Science
2013English

miR-155 Meets the JAK/STAT Pathway

Cell Cycle
MedicineDevelopmental BiologyCell BiologyMolecular Biology
2013English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy